deltatrials
Terminated PHASE2 INTERVENTIONAL 4-arm NCT05935748

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination With Palbociclib (Doublet) and With Palbociclib and Sasanlimab (Triplet) in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Sponsor: NiKang Therapeutics, Inc.

Conditions Adenocarcinoma Advanced Renal Cell Carcinoma Carcinoma Carcinoma, Renal Cell Clear Cell Renal Cell Carcinoma Kidney Cancer Kidney Diseases Kidney Neoplasms Metastatic Renal Cell Carcinoma Neoplasm by Histology Neoplasms Neoplasms by Site Neoplasms, Glandular and Epithelial Recurrent Renal Cell Carcinoma Refractory Renal Cell Carcinoma Renal Cancer Renal Neoplasms Urogenital Neoplasms Urologic Diseases Urologic Neoplasms ccRCC
Interventions NKT2152 palbociclib sasanlimab
Updated 11 times since 2023 Last updated: Nov 10, 2025 Started: Jul 28, 2023 Primary completion: Jun 30, 2025 Completion: Sep 4, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was terminated as a result of Sponsor portfolio reprioritization.

Other terminated trials from NiKang Therapeutics, Inc.

More terminations from NiKang Therapeutics, Inc.

Other Adenocarcinoma trials with similar outcome

Browse all Adenocarcinoma trials

Listed as NCT05935748, this PHASE2 trial focuses on Adenocarcinoma and Advanced Renal Cell Carcinoma and remains terminated or withdrawn. Sponsored by NiKang Therapeutics, Inc., it has been updated 11 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Apr 2024 · 3 months · monthly snapshotRecruiting~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Feb 2025 · 3 months · monthly snapshotActive Not Recruiting~Feb 2025 – ~Dec 2025 · 10 months · monthly snapshotActive Not Recruiting~Dec 2025 – present · 9 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Dec 2025 — Present [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Feb 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

▶ Show 6 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  2. Jan 2024 — Apr 2024 [monthly]

    Recruiting PHASE2

  3. Nov 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  4. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  5. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  6. Aug 2023 — Sep 2023 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Jul 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NiKang Therapeutics, Inc.
  • Pfizer
Data source: NiKang Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations